Proqr Therapeutics NV 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
ProQR Therapeutics N.V. reported increased net losses for 2025, driven by higher R&D costs for its RNA editing platform, while advancing its pipeline and securing partnerships.
NASDAQ
20-F: ProQR Therapeutics N.V. Files 20-F Report, Details Financials and Strategic Focus on RNA Editing
ProQR Therapeutics N.V. releases its 20-F filing, highlighting its financial results for the year ended December 31, 2024, and outlining its strategic focus on its Axiomer RNA editing platform.
NASDAQ
ProQR Therapeutics' 2023 annual report highlights a strategic pivot towards RNA editing platforms, accompanied by financial results reflecting ongoing investments and a divestiture of ophthalmology assets.